Acasti Pharma reported a GAAP earnings per share (EPS) of -$1.35, driven by high R&D investments, pandemic-related disruptions, and operational costs. Despite current fiscal challenges, the company's drug pipeline and strategic partnerships provide a hopeful outlook for future growth.
